Catalyst Pharmaceuticals (CPRX)
(Real Time Quote from BATS)
$22.24 USD
-0.63 (-2.76%)
Updated Jan 23, 2025 11:18 AM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Earnings News For CPRX
-
Why Is Catalyst (CPRX) Down 6.7% Since Last Earnings Report?
-
Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates
-
Why Is Catalyst (CPRX) Up 8.3% Since Last Earnings Report?
-
Catalyst (CPRX) Rises as Q2 Earnings & Revenues Beat Estimates
-
Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates
-
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
-
Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
-
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
-
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
-
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
-
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?
-
Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up
-
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates
-
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Why Is Catalyst (CPRX) Up 16.2% Since Last Earnings Report?
-
Catalyst (CPRX) Q3 Earnings Miss, Sales Top, '23 View Up
-
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
-
Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?
-
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
-
Why Is Catalyst (CPRX) Down 14% Since Last Earnings Report?
-
Catalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook Raised
-
Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates
-
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
-
Catalyst (CPRX) Down 16.2% Since Last Earnings Report: Can It Rebound?
-
Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023